All In Biotech

Drug Trial Radar · NCT04494412

An Intravenous (IV) Zanamivir Pharmacokinetics (PK) Study in Hospitalized Neonates and Infants With Influenza Infection

An Open Label, Single Arm Study to Evaluate Single and Multiple Dose Pharmacokinetics, Safety and Tolerability, and to Explore Clinical Outcomes of Treatment With Intravenous (IV) Zanamivir in Neonates and Infants Under 6 Months of Age With Confirmed Complicated Influenza Infection

Last checked: Nov 20, 2026Latest source record: Jul 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

8

Actual

Start

Nov 21, 2022

Primary completion

Jan 14, 2026

Study completion Apr 1, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 31, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, up to 6 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Influenza infection is an important public health priority, with seasonal outbreaks and pandemics causing considerable global morbidity and mortality. The PK, pharmacodynamics (PD), safety and efficacy of IV zanamivir have been evaluated in adults, adolescents and infants more than or equal to (\>=) 6 months of age with hospitalized influenza in the IV zanamivir global development program. However, antiviral treatment of neonates and infants under 6 months of age hospitalized with influenza infection remains a medical unmet need. Given the immaturity of the immune system at this age, there are no licensed influenza vaccines for children aged less than six months old. As a requirement of the Pediatric Investigation Plan European Union (EU), GlaxoSmithKline (GSK) will be conducting this open-label, multi-center, single arm, post-marketing authorization study to evaluate the PK and collect safety and tolerability information of IV zanamivir in hospitalized neonates and infants under 6 months of age with confirmed complicated influenza infection. The total duration of study participation for each participant will be up to 24 days with a study treatment period up to 10 days and 14 days of post-treatment follow up. However, for a given participant, the initial 5-day treatment course may be extended for up to 5 additional days if clinical symptoms, participant characteristics or virological tests as assessed by the investigator warrant further treatment. DECTOVA is a trademark of GlaxoSmithKline group of companies.

Conditions

  • Influenza, Human
  • Arthralgia

Interventions

  • ZanamivirDrug

    Zanamivir solution for infusion will be available as a 10 milligrams per milliliters (mg/mL) vial. DECTOVA is approved for age groups 6 months and above.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the serum concentration-time curve (AUC) of zanamivirTime frame: Up to 12 hours after end of infusion on Day 1
  2. Maximum observed serum concentration (Cmax) of zanamivirTime frame: Up to 12 hours after end of infusion on Day 1
  3. Clearance (CL) in plasma following administration of zanamivirTime frame: 30 minutes, 2 hours, 6 hours, 12 hours post dose on Day 1; predose on Days 3, 4 or 5
  4. Terminal half-life (t1/2) of zanamivirTime frame: 30 minutes, 2 hours, 6 hours, 12 hours post dose on Day 1; predose on Days 3, 4 or 5

Locations

6 sites in 3 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Florence, Italy

  • GSK Investigational Site

    Messina, Italy

  • GSK Investigational Site

    Roma, Italy

  • GSK Investigational Site

    Bydgoszcz, Poland

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.